SG11201907646YA - Proteins binding her2, nkg2d and cd16 - Google Patents

Proteins binding her2, nkg2d and cd16

Info

Publication number
SG11201907646YA
SG11201907646YA SG11201907646YA SG11201907646YA SG11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA
Authority
SG
Singapore
Prior art keywords
international
lebanon
lucent
pct
drive
Prior art date
Application number
SG11201907646YA
Other languages
English (en)
Inventor
Gregory Chang
Ann Cheung
William Haney
Bradley Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG11201907646YA publication Critical patent/SG11201907646YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)
SG11201907646YA 2017-02-20 2018-02-20 Proteins binding her2, nkg2d and cd16 SG11201907646YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461146P 2017-02-20 2017-02-20
PCT/US2018/018771 WO2018152518A1 (fr) 2017-02-20 2018-02-20 Protéines se liant à her2, nkg2d et cd16

Publications (1)

Publication Number Publication Date
SG11201907646YA true SG11201907646YA (en) 2019-09-27

Family

ID=63170743

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907646YA SG11201907646YA (en) 2017-02-20 2018-02-20 Proteins binding her2, nkg2d and cd16

Country Status (15)

Country Link
US (1) US11884732B2 (fr)
EP (2) EP4273258A3 (fr)
JP (3) JP2020508997A (fr)
KR (2) KR20240060739A (fr)
CN (1) CN110944661A (fr)
AU (1) AU2018220736A1 (fr)
BR (1) BR112019017197A2 (fr)
CA (2) CA3054079A1 (fr)
DK (1) DK3582806T3 (fr)
ES (1) ES2955074T3 (fr)
FI (1) FI3582806T3 (fr)
IL (1) IL268755A (fr)
MX (1) MX2019009848A (fr)
SG (1) SG11201907646YA (fr)
WO (1) WO2018152518A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190118172A (ko) * 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
FI3582806T3 (fi) 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
KR20200118080A (ko) 2018-02-08 2020-10-14 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d 수용체를 표적화하는 항체 가변 도메인
TW201942134A (zh) * 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
TW202033547A (zh) 2018-10-23 2020-09-16 美商蜻蜓醫療公司 異二聚體fc融合蛋白
JP2022546454A (ja) * 2019-08-30 2022-11-04 ドラゴンフライ セラピューティクス， インコーポレイテッド がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
CN112029001B (zh) * 2020-09-02 2022-09-06 南京北恒生物科技有限公司 靶向nk激活性受体的嵌合抗原受体
WO2022258691A1 (fr) * 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a
WO2024056861A1 (fr) 2022-09-15 2024-03-21 Avidicure Ip B.V. Protéines de liaison à un antigène multispécifiques pour stimuler des cellules nk et utilisation associée

Family Cites Families (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (fr) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Anticorps monoclonaux contre le carcinome des cellules renales
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
EP0415929A1 (fr) 1988-01-15 1991-03-13 Centocor, Inc. Anticorps formant des heteroligats et leurs emplois therapeutiques
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2131528C (fr) 1992-03-05 2004-07-13 Philip E. Thorpe Agents diagnostiques et/ou therapeutiques cibles pour les cellules endotheliales neovasculaires
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69636015T2 (de) 1995-05-03 2007-01-04 Bioenhancementsments Ltd. Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
DE19531346A1 (de) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
ES2293748T3 (es) 1998-10-21 2008-03-16 Altor Bioscience Corporation Moleculas de fijacion poliespecificas y usos de las mismas.
HUP0300919A2 (hu) 2000-03-24 2003-07-28 Micromet Ag Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel
JP2004511430A (ja) 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
UA87979C2 (ru) 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
KR20050108349A (ko) 2003-02-06 2005-11-16 마이크로메트 에이지 영속적인 티 세포 반응을 유도하는 삼량체 폴리펩티드 구조물
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN100453556C (zh) 2003-10-16 2009-01-21 麦克罗梅特股份公司 多特异性的去免疫化cd3结合物
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
EP1716178B1 (fr) 2004-02-16 2010-08-11 Micromet AG Molecules de liaison moins immunogenes
US8518403B2 (en) 2004-07-16 2013-08-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
ES2521140T3 (es) * 2004-07-22 2014-11-12 Genentech, Inc. Composición de anticuerpos de HER2
AU2005291039A1 (en) 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
JP2009500346A (ja) 2005-06-29 2009-01-08 ユニバーシティー・オブ・マイアミ 癌処置用の抗体−免疫細胞リガンド融合タンパク質
WO2007022520A2 (fr) 2005-08-19 2007-02-22 Cerus Corporation Renfort induit par anticorps de reponse immune
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
EP2322557B1 (fr) 2005-10-14 2017-08-30 Innate Pharma Compositions et procédés pour traiter des maladies prolifératives
US20080299137A1 (en) 2005-10-28 2008-12-04 Novo Nordisk A/S Fusion Proteins That Bind Effector Lymphocytes And Target Cells
EP1949107A1 (fr) 2005-11-03 2008-07-30 Fred Hutchinson Cancer Research Center Immunomodulation negative des reponses immunitaires de cellules cd4 nkg2d-positives
WO2007097812A2 (fr) 2005-11-03 2007-08-30 Genentech, Inc. Polypeptides thérapeutiques de fusion d'anticorps anti-her2
CA2633594C (fr) 2005-12-16 2021-10-26 Micromet Ag Moyens et procedes pour le traitement de maladies tumorales
EP1820513A1 (fr) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
EP1900752A1 (fr) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Anticorps monoclonaux humains et ses fragments liant spécifiquement le récepteur alpha de l'acide folique pour l'immunothérapie du cancer de l'ovaire
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
EP2014680A1 (fr) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
JP5591712B2 (ja) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
WO2009094148A2 (fr) 2008-01-22 2009-07-30 Biogen Idec Ma Inc. Anticorps ron et leurs utilisations
NZ589436A (en) * 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US20100124764A1 (en) 2008-09-26 2010-05-20 Wyeth Single chain antibody library design
JP2012508017A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
EP2376105B1 (fr) 2008-12-18 2015-07-29 Dana-Farber Cancer Institute, Inc. Nkg2d-fc pour immunothérapie
EP2376109B1 (fr) 2008-12-19 2019-01-23 MacroGenics, Inc. Diabodies covalents et leurs utilisations
SG175081A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
WO2010132697A2 (fr) 2009-05-13 2010-11-18 Genzyme Corporation Procédés et compositions de traitement
WO2010144295A1 (fr) 2009-06-09 2010-12-16 University Of Miami Aptamère ligand co-stimulateur ciblé par un aptamère
SG177560A1 (en) 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011030851A1 (fr) 2009-09-11 2011-03-17 タカラバイオ株式会社 Procédé de production de cellules tueuses naturelles
NZ598732A (en) 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
WO2011057124A1 (fr) 2009-11-06 2011-05-12 Transtarget, Inc. Compositions d'anticorps bispécifiques polyclonaux et méthode d'utilisation
EP2332994A1 (fr) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Thérapie trispécifique contre la leucémie myéloïde aiguë
WO2011075636A2 (fr) 2009-12-18 2011-06-23 Amgen Inc. Épitopes et agents de liaison destinés à wise
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
WO2011085178A1 (fr) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Protéine de fusion monomérique bispécifique
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PE20170779A1 (es) 2010-03-04 2017-07-04 Macrogenics Inc Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
JP6029581B2 (ja) 2010-06-19 2016-11-24 メモリアル スローン−ケタリング キャンサー センター 抗ｇｄ２抗体
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
DE102010039018B4 (de) 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
CA2807278A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Anticorps bispecifiques comprenant un fragment fv stabilise par bisulfure
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
WO2012032080A1 (fr) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Fc humain stabilisé
WO2012034039A2 (fr) 2010-09-10 2012-03-15 Apexigen, Inc. Anticorps anti-il-1 bêta et leurs procédés d'utilisation
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
WO2012064792A2 (fr) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Complexes protéiques pour la liaison à un antigène, et leurs procédés d'utilisation
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
ES2668895T3 (es) 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
EP2688909A2 (fr) 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Immunoglobulines hétéro-dimériques
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
WO2012162068A2 (fr) 2011-05-21 2012-11-29 Macrogenics, Inc. Domaines de liaison du sérum déimmunisé et leur utilisation pour prolonger la demi-vie du sérum
AU2012258637B2 (en) 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
CN103827300A (zh) 2011-06-30 2014-05-28 中外制药株式会社 异源二聚化多肽
DE102011118022B4 (de) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
CN103687879B (zh) 2011-07-22 2016-05-04 阿菲姆德农业医药公司 多价抗原结合fv分子
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
EP2762493B1 (fr) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
MX366269B (es) 2011-09-30 2019-07-04 Chugai Pharmaceutical Co Ltd Biblioteca de moleculas de union dependientes de la concentracion ionica.
SI2794658T1 (sl) 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
JP6335796B2 (ja) 2012-02-08 2018-06-06 アイジーエム バイオサイエンシズ インク．Ｉｇｍ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｃｄｉｍ結合タンパク質及びその使用
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
TWI797443B (zh) 2012-05-30 2023-04-01 日商中外製藥股份有限公司 抗原結合分子之篩選或製造方法
WO2013187495A1 (fr) 2012-06-14 2013-12-19 中外製薬株式会社 MOLÉCULE DE LIAISON À L'ANTIGÈNE CONTENANT UNE RÉGION Fc MODIFIÉE
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
EP2872170A4 (fr) 2012-07-13 2016-06-22 Zymeworks Inc Hétérodimères asymétriques bispécifiques comprenant des produits de recombinaison anti-cd3
AU2013293092A1 (en) 2012-07-23 2015-02-26 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
NZ630563A (en) 2012-09-27 2017-04-28 Merus Nv Bispecific igg antibodies as t cell engagers
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
AU2013352812B2 (en) 2012-11-27 2019-06-20 Ajou University Industry-Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
MX2015008740A (es) * 2013-01-10 2015-10-26 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
CA2898100C (fr) 2013-01-14 2023-10-10 Xencor, Inc. Nouvelles proteines heterodimeres
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
EP2948475A2 (fr) 2013-01-23 2015-12-02 AbbVie Inc. Procédés et compositions pour la modulation du systéme immunitaire
WO2014122144A1 (fr) 2013-02-05 2014-08-14 Engmab Ag Anticorps bispécifiques anti-cd3ɛ et bcma
NZ708182A (en) 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
RU2020115527A (ru) 2013-03-14 2020-07-07 Макродженикс, Инк. Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2951203B1 (fr) * 2013-03-15 2019-05-22 Xencor, Inc. Protéines hétérodimériques
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
WO2014165818A2 (fr) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions et méthodes de prévention et de traitement du cancer de la prostate
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
SG11201509259RA (en) 2013-05-10 2015-12-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
WO2014198748A1 (fr) 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps à domaine unique anti-her2, polypeptides comportant de tels anticorps et leur utilisation pour le traitement du cancer
TW201536810A (zh) 2013-07-15 2015-10-01 Novo Nordisk As 結合尿激酶纖維蛋白溶酶原活化物之抗體
ES2819209T3 (es) 2013-07-16 2021-04-15 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de TIGIT
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
JP6599338B2 (ja) 2013-09-16 2019-10-30 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー） Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
EP3066130B1 (fr) 2013-11-07 2019-05-15 Memorial Sloan-Kettering Cancer Center Anticorps bispécifique anti-wt1/hla
DE102013019352A1 (de) 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
WO2015089344A1 (fr) 2013-12-13 2015-06-18 Genentech, Inc. Anticorps et immunoconjugués anti-cd33
WO2015095412A1 (fr) 2013-12-19 2015-06-25 Zhong Wang Anticorps bispécifique comprenant deux fragments de liaison à l'antigène à domaine unique
CA2925677A1 (fr) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Anticorps bispecifiques anti-het2 et leurs methodes d'utilisation
KR102597804B1 (ko) 2013-12-20 2023-11-07 제넨테크, 인크. 이중 특이적 항체
WO2015095972A1 (fr) 2013-12-23 2015-07-02 The Centre For Drug Research And Development Anticorps comportant des extensions polypeptidiques c-terminales à chaîne légère et leurs conjugués et procédés d'utilisation
CA2931641C (fr) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs d'immunoglobuline en tandem et leurs utilisations
AU2015206407A1 (en) 2014-01-15 2016-08-18 Zymeworks Inc. Bi-specific CD3 and CD19 antigen-binding constructs
US20170066827A1 (en) 2014-03-05 2017-03-09 Ucl Business Plc Chimeric antigen receptor
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
US20170022291A1 (en) 2014-04-01 2017-01-26 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
SI3560954T1 (sl) 2014-04-03 2021-11-30 Igm Biosciences, Inc. Spremenjena J-veriga
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
EP2930188A1 (fr) 2014-04-13 2015-10-14 Affimed Therapeutics AG Molécule de liaison à l'antigène trifonctionnel
EP2942629A1 (fr) 2014-05-08 2015-11-11 Universität Würzburg Marqueurs prédictifs pour immunothérapie du cancer réussie
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
EP3954703A3 (fr) 2014-05-29 2022-05-18 MacroGenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
WO2015197582A1 (fr) 2014-06-27 2015-12-30 Innate Pharma Protéines monomères multispécifiques de liaison aux antigènes
US11208480B2 (en) 2014-06-27 2021-12-28 Innate Pharma Multispecific antigen binding proteins
AU2015292755B2 (en) 2014-07-21 2020-11-12 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
US10556964B2 (en) 2014-07-21 2020-02-11 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
CA2958200A1 (fr) 2014-08-14 2016-02-18 Novartis Ag Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4
EP2985294A1 (fr) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Molécule d'anticorps de recombinaison et son utilisation pour l'activation des lymphocytes T restreints de cellule cible
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN107106677A (zh) 2014-08-28 2017-08-29 莱顿大学学术医院以Lumc的名义运作 Cd94/nkg2a和/或cd94/nkg2b抗体、疫苗组合
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
US11001640B2 (en) 2014-11-03 2021-05-11 Merck Patent Gmbh Methods for generating bispecific shark variable antibody domains and use thereof
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
HUE058851T2 (hu) 2014-12-05 2022-09-28 Xyphos Biosciences Inc Inzertálható variábilis antitestfragmentumok és az NKG2D ligandumok módosított A1-A2 doménjei
US20160176983A1 (en) 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
CN107406509B (zh) 2014-12-19 2021-10-29 凯奥目生物科学株式会社 包含结合至5t4和cd3的三个结合结构域的融合蛋白
WO2016109774A1 (fr) 2015-01-02 2016-07-07 Dyax Corp. Anticorps bispécifiques agissant à l'encontre la kallicréine plasmatique et du facteur xii
WO2016115274A1 (fr) 2015-01-14 2016-07-21 Compass Therapeutics Llc Constructions de liaison à des antigènes immunomodulateurs multispécifiques
TW201627322A (zh) * 2015-01-26 2016-08-01 宏觀基因股份有限公司 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子
CA2977350C (fr) 2015-02-20 2022-08-23 Ohio State Innovation Foundation Anticorps bivalent dirige contre nkg2d et antigenes associes a une tumeur
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
WO2016142768A1 (fr) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Anticorpd anti-ror2
WO2016146702A1 (fr) 2015-03-16 2016-09-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Molécules de liaison trispécifiques pour le traitement d'une infection par le vhb et d'états pathologiques associés
US20180208658A1 (en) 2015-04-03 2018-07-26 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
WO2016164308A1 (fr) 2015-04-06 2016-10-13 Subdomain, Llc Polypeptides contenant un domaine de liaison de novo et leurs utilisations
CA2981851A1 (fr) 2015-04-07 2016-10-13 Alector Llc Anticorps anti-sortiline et leurs methodes d'utilisation
WO2016166139A1 (fr) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Protéines de fusion bispécifiques pour augmenter les réponses immunitaires de lymphocytes contre des cellules tumorales
EP3842072A1 (fr) 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anticorps anti-ror1
EP3095792A1 (fr) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München Récepteur de lymphocytes t avec une spécificité pour le peptide de myéloperoxydase et leurs utilisations
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
HRP20230060T1 (hr) 2015-05-29 2023-03-17 Bristol-Myers Squibb Company Antitijela protiv ox40 i njihova primjena
EP3307779A2 (fr) 2015-06-12 2018-04-18 Alector LLC Anticorps anti-cd33 et leurs procédés d'utilisation
US20160361360A1 (en) 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US10113003B2 (en) 2015-06-23 2018-10-30 Innate Pharma Multispecific NK engager proteins
CA2990511A1 (fr) 2015-06-23 2016-12-29 Innate Pharma Proteines qui se lient a des antigenes multispecifiques
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
WO2017011342A1 (fr) 2015-07-10 2017-01-19 Abbvie Inc. Protéines de liaison modifiées par igm ou ige et leurs utilisations
EP3322735A4 (fr) 2015-07-15 2019-03-13 Zymeworks Inc. Constructions bispécifiques de liaison à un antigène conjuguées à un médicament
EP3322449A1 (fr) 2015-07-16 2018-05-23 Cellerant Therapeutics, Inc. Immunoglobulines substituées par un résidu cystéine
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
WO2017048824A1 (fr) 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions et procédés de traitement du cancer par antagonisme de la voie cd155/tighit et de tgf-ss
CN108602887B (zh) 2015-10-02 2022-06-21 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
SG11201803567XA (en) 2015-10-29 2018-05-30 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
KR20180083874A (ko) 2015-11-04 2018-07-23 사울 제이. 프라이스맨 Her2를 표적화하는 키메라 항원 수용체
WO2017083545A1 (fr) 2015-11-10 2017-05-18 Fred Hutchinson Cancer Research Center Leurres nkg2d
EP3374389A1 (fr) 2015-11-13 2018-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps à domaine unique anti-nkg2d et utilisations de ceux-ci
WO2017114694A1 (fr) 2015-12-28 2017-07-06 Innate Pharma Régions variables de protéines se liant à nkp46
AU2017207480A1 (en) 2016-01-13 2018-08-02 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
ES2847155T3 (es) 2016-01-21 2021-08-02 Novartis Ag Moléculas multiespecíficas que fijan como objetivo CLL-1
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CN109310766A (zh) 2016-02-26 2019-02-05 伊蒙纽斯私人有限公司 多特异性分子
AU2017238172B2 (en) 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3432924A1 (fr) 2016-03-23 2019-01-30 Novartis AG Mini-corps sécrétés par des cellules et leurs usages
US20190111079A1 (en) 2016-04-15 2019-04-18 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
UA127341C2 (uk) 2016-04-15 2023-07-26 Мекроудженікс, Інк. Виділена b7-н3-зв'язувальна молекула
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
CA3026151A1 (fr) 2016-06-14 2017-12-21 Xencor, Inc. Anticorps inhibiteurs de points de controle bispecifiques
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN105906722B (zh) 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 一种Her2特异性嵌合抗原受体及其应用
AU2017319519A1 (en) 2016-09-01 2019-04-18 Immunomab, Inc. Bispecific antibodies
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
KR20190118172A (ko) * 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
US20200095327A1 (en) 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
CA3053275A1 (fr) 2017-02-10 2018-08-16 Dragonfly Therapeutics, Inc. Proteines fixant le psma, le nkg2d et le cd16
CN110461361A (zh) 2017-02-10 2019-11-15 蜻蜓治疗公司 结合bcma、nkg2d和cd16的蛋白
AU2018220748A1 (en) 2017-02-20 2019-09-12 Dragonfly Therapeutics, Inc. Proteins binding GD2, NKG2D and CD16
JP2020510646A (ja) 2017-02-20 2020-04-09 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
JP2020508998A (ja) 2017-02-20 2020-03-26 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ１２３、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
FI3582806T3 (fi) 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
WO2018157147A1 (fr) 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Protéines de liaison multi-spécifiques ciblant caix, ano1, la mésothéline, trop2, cea ou la claudine-18.2
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
US20200157227A1 (en) 2017-05-23 2020-05-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
WO2018217799A1 (fr) 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. Protéine de liaison à nkg2d, cd16 et ror1 ou ror2
CA3064567A1 (fr) 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. Proteine de liaison nkg2d, cd16 et antigene associe a une tumeur
CN111132698A (zh) 2017-07-31 2020-05-08 蜻蜓治疗公司 结合nkg2d、cd16以及flt3的蛋白质
CA3176049A1 (fr) 2017-08-16 2019-02-21 Dragonfly Therapeutics, Inc. Proteines liant nkg2d, cd16 et egfr, ccr4 ou pd-l1
EP3672993A4 (fr) 2017-08-23 2021-10-27 Dragonfly Therapeutics, Inc. Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
CN113004417A (zh) 2017-09-07 2021-06-22 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN111432832A (zh) 2017-09-14 2020-07-17 蜻蜓疗法股份有限公司 结合nkg2d、cd16和c-型凝集素样分子-1(cll-1)的蛋白质
CN112040971A (zh) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
KR20200118080A (ko) 2018-02-08 2020-10-14 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d 수용체를 표적화하는 항체 가변 도메인
EA202091976A1 (ru) 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на cd33, и их применение
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
US20210221894A1 (en) 2018-04-03 2021-07-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
EP3790585A4 (fr) 2018-05-07 2022-05-11 Dragonfly Therapeutics, Inc. Protéine de liaison au nkg2d, au cd16 et à un antigène associé à une tumeur
JP7494129B2 (ja) 2018-05-16 2024-06-03 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033702A1 (fr) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Protéines de liaison à nkg2d, à cd16 et antigène associé à une tumeur
EP3990476A1 (fr) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Protéines de fusion flt3l-fc et procédés d'utilisation
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
JP2022546454A (ja) 2019-08-30 2022-11-04 ドラゴンフライ セラピューティクス， インコーポレイテッド がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质

Also Published As

Publication number Publication date
AU2018220736A1 (en) 2019-09-05
DK3582806T3 (da) 2023-09-11
CA3235295A1 (fr) 2018-08-23
IL268755A (en) 2019-10-31
ES2955074T3 (es) 2023-11-28
JP2024024048A (ja) 2024-02-21
KR20190120782A (ko) 2019-10-24
BR112019017197A2 (pt) 2020-04-14
EP3582806A4 (fr) 2020-12-16
CA3054079A1 (fr) 2018-08-23
EP4273258A2 (fr) 2023-11-08
EP4273258A3 (fr) 2024-01-17
EP3582806A1 (fr) 2019-12-25
CN110944661A (zh) 2020-03-31
JP2022101687A (ja) 2022-07-06
US11884732B2 (en) 2024-01-30
US20200231678A1 (en) 2020-07-23
EP3582806B1 (fr) 2023-07-26
KR20240060739A (ko) 2024-05-08
WO2018152518A1 (fr) 2018-08-23
JP2020508997A (ja) 2020-03-26
MX2019009848A (es) 2019-12-19
FI3582806T3 (fi) 2023-09-07

Similar Documents

Publication Publication Date Title
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201907271PA (en) Proteins binding psma, nkg2d and cd16
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201907648XA (en) Proteins binding gd2, nkg2d and cd16
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201907870VA (en) Compositions and methods for inhibition of lineage specific proteins
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907846VA (en) Therapeutic rna
SG11201900501RA (en) Cannabis composition
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201907645PA (en) Proteins binding cd123, nkg2d and cd16
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof